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Abstract: Fanconi anemia (FA) is an autosomal recessive disorder characterized by congenital abnormalities, bone marrow 
failure, chromosome fragility, and cancer susceptibility. At least eleven members of the FA gene family have been identiﬁ  ed 
using complementation
 experiments. Ubiquitin-proteasome has been shown to be a key regulator of FA proteins and their 
involvement in the repair of DNA damage. Here, we identiﬁ  ed a novel functional link between the FA/BRCA pathway and 
E2F-mediated cell cycle regulome. In silico mining of a transcriptome database and promoter analyses revealed that a 
signiﬁ  cant number of FA gene members were regulated by E2F transcription factors, known to be pivotal regulators of cell 
cycle progression – as previously described for BRCA1. Our ﬁ  ndings suggest that E2Fs partly determine cell fate through 
the FA/BRCA pathway. 
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Introduction
Fanconi anemia (FA) is an autosomal recessive disorder characterized by congenital abnormalities, 
bone marrow failure, chromosome fragility, and cancer susceptibility (Joenje and Patel, 2001). To date, 
at least eleven members of this family, including FANCA,
 FANCB,
 FANCC, FANCD1 (alias BRCA2), 
FANCD2, FANCE, FANCF, FANCG (alias XRCC9), FANCJ,
 FANCL,
 and
 FANCM (Joenje and Patel 
2001), have been identiﬁ  ed using complementation
 experiments. Among them, eight FA-associated 
genes have been identiﬁ  ed so far (FANCA,
 FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and
 
FANCL (Strathdee et al. 1992; Joenje and Patel, 2001; Timmers et al. 2001; Howlett et al. 2002; Meetei 
et al. 2003). The FANCA, FANCC, FANCE, FANCF, FANCG, and FANCL proteins are part of a nuclear 
multiprotein core complex that triggers the monoubiquitination of the FANCD2 protein during S phase 
of the cell cycle and after exposure to DNA crosslinking agents (Garcia-Higuera et al. 2001; Meetei 
et al. 2003; Soulier et al. 2005). Monoubiquitinated
 FANCD2 colocalizes in nuclear foci with BRCA1, 
FANCD1, and NBS1 (Garcia-Higuera et al. 2001; Howlett et al. 2002; Nakanishi et al. 2002). This 
evidence suggests a link between the FA protein complex and the cellular BRCA1 repair machinery. 
Therefore, the FA/BRCA pathway is thought to be involved in the repair of DNA damage to maintain 
genomic integrity (D’Andrea and Grompe, 2003). The cellular targets of the FA/BRCA pathway remain 
unknown. 
A remarkably high clinical variability exists among FA patients (Auerbach et al. 2001; Alter, 2003). 
Besides the ubiquitination of FA proteins, other regulatory mechanisms may affect the expression level 
of FA proteins; such regulatory mechanisms may contribute to the clinical variability observed among 
FA patients. Bioinformatics is a useful tool for integrating complex gene functions. It also allows the 
establishment of biological frameworks or “system biology”. It is believed to connect between gene 
regulation and phenotypes. Our current standard concept for gene regulation can be roughly divided 
into two aspects; namely, gene transcription and protein degradation. If the signiﬁ  cant regulators of 
gene transcription or protein degradation for each component of complex gene networks could be 
revealed, one could easily imagine the gene network and extract the phenotypes of cells or model organ-
isms. As a logical consequence, system biology views are an unavoidable necessity for current biology 
studies. 
We have focused on the E2F transcription factor-regulated transcriptome because E2F family members 
integrate the upstream signals to the downstream target genes during the monitoring of proper cell cycle Gene Regulation and Systems Biology 2007: 1 2
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progression. Indeed, the downstream target genes 
of E2F1 can be divided into several categories 
including DNA replication, DNA damage/repair, 
apoptosis, differentiation, and development 
(Bracken et al. 2004). Evidence that E2F family 
members regulate BRCA1 expression and interact 
with BRCA1 protein (Wang et al. 2000; Oberley 
et al. 2003; Bindra and Glazer, 2006) prompted us 
to investigate comprehensively the relationship 
between E2Fs and FA genes.
In the present study, we evaluated
 the possible 
link between E2F transcription factors and FA 
genes by analyzing the FA gene promoters in silico 
followed by a luciferase-based promoter assay. 
These analyses, combined
 with a public microarray 
data search, allowed us to identify a novel aspect 
of the FA pathway that is partially regulated in a 
cell cycle-dependent manner via E2Fs. The 
discovery that both FA genes and BRCA1 are under 
the control of E2Fs suggests that the FA/BRCA 
pathway is an effector of E2F-regulated cell cycle 
progression and DNA damage/repair signaling. 
Comprehensive regulome analyses of the FA gene 
using cell cycle-associated transcriptional factors 
may enable us to open a new window onto the 
system biology of FA genes. 
Materials & Methods
Bioinformatics 
The E2F1 gene expression proﬁ  le identiﬁ  ed using 
adenovirus-mediated gene transfer in SKMEL-2 
melanoma cells (Affymetrix GeneChip analysis 
(Jamshidi-Parsian et al. 2005)) was deposited in 
the Gene Expression Omnibus (GEO), which is 
maintained by The National Center for Biotech-
nology Information (NCBI, NIH) (http://www.
ncbi.nlm.nih.gov/). By searching the database, 
FANCA (Probe No. 33145), FANCC (Probe Nos. 
35713, 1982_s, and 160034_s), FANCD1 (Probe 
Nos. 1503, 1989, and 1990_g), FANCG (Probe No. 
37584), and FANCL (Probe No. 33125) mRNAs 
were identiﬁ  ed (Accession No. GDS1078; Plat-
form No. GPL91). The expression profile 
suggested by an analysis of the EST (expressed 
sequence tag) counts in human tissues and organs 
was searched using the UniGene database (EST 
Proﬁ  le Viewer, NCBI, NIH). The data sets used 
for the FA genes are shown in Table 1. The number 
of transcripts per million was calculated based on 
the gene EST/total EST in the pool, and this value 
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was exported to an Excel ﬁ  le. Transfac software 
(http://motif.genome.jp/) was then used to deter-
mine the E2F family of transcription factors 
binding-elements. 
Plasmids
The human FA promoter fragments were generated 
using polymerase chain reaction (PCR) from 
genomic DNA, and ligated into pGL3-Basic vectors 
(Promega, Madison, WI, U.S.A). PCR primers were 
designed to amplify 318-bp (–274/+44), 333-bp 
(–263/+70), 298-bp (–232/+66), 318-bp (–286/+32), 
224-bp (–208/+16), 1330-bp (–1287/+43), 328-bp 
(–373/+37), 442-bp (–441/+1), 256-bp (–249/+7), 
860-bp (–835/+25), and 410-bp (–732/–128) frag-
ments of the human FANCA, FANCB, FANCC, 
FANCD1, FANCD2, FANCE, FANCF, FANCG, 
FANCJ, FANCL, and FANCM promoter sequences, 
respectively; the above numbering is relative to the 
transcription initiation site at +1, described in the 
UniGene Database (Genome View, NCBI, NIH). 
The GenBank Accession numbers of the genomic 
clones used for the designation of the PCR primers 
are shown in Table 1. A KpnI site was added to the 
forward primer and a BglII site was added to the 
reverse primer to facilitate the subcloning of the 
promoter regions of FANCA, FANCB, FANCC, 
FANCD1, FANCD2, FANCF, FANCG, FANCJ, 
FANCL, and FANCM, respectively. A KpnI site was 
added to the forward primer and a HindIII site was 
added to the reverse primer to facilitate the 
subcloning of the promoter region of FANCE. The 
following plasmids that were used have been previ-
ously described: pcDNA3-E2F1, E2F2, E2F3, 
E2F4, E2F5, and E2F6 (Yoshida and Inoue, 2004; 
Hayashi et al. 2006).
Cell culture and luciferase assay 
HeLa and WI-38 cells were cultured in Earle’s 
modiﬁ  ed Eagle’s medium (Invitrogen, Carlsbad, 
CA, U.S.A) supplemented with 10% fetal bovine 
serum and antibiotics. Preparation of the adeno-
virus, the virus infection procedure, and the Western 
blot analysis were as described previously (Goto 
et al. 2006). For the promoter assay, 2 × 10
4 HeLa 
cells were transfected with FuGENE6, in accor-
dance with the manufacturer’s instructions (Roche 
Diagnostic, Basel, Switzerland). Brieﬂ  y, 400 ng of 
the expression plasmid, 200 ng of the ﬁ  reﬂ  y lucif-
erase reporter plasmid (pGL3, Promega, Madison, 
WI, U.S.A.), and 0.6 ng of the Renilla luciferase 
reporter plasmid (pRL-TK, Promega, Madison, WI, 
U.S.A.) per 24-well dish were used for each trans-
fection. The cells were harvested 24 hours after the 
transfection, and a luciferase assay was performed 
using the Dual-Luciferase Reporter Assay System, 
in accordance with the manufacturer’s protocol 
(Promega, Madison, WI, U.S.A.). As a control for 
transfection efﬁ  ciency, the ﬁ  reﬂ  y luciferase activity 
values were normalized to the Renilla luciferase 
activity values. Data are presented as the mean 
values ± standard deviation. 
RT (reverse transcriptase)-PCR
Total cellular RNA was extracted from the WI-38 
cells using an RNeasy Mini Kit (Qiagen, Valencia, 
CA, U.S.A.), in accordance with the manufactur-
er’s instructions. The RT step was
 also performed 
according to the manufacturer’s directions 
(Invitrogen, Carlsbad, CA, U.S.A.).
 Brieﬂ  y, 500 
ng of extracted RNA, oligo(dT) primer, and 1 × 
annealing buffer were diluted in 8 µL
 of RNase/
DNase-free water, heated to 65 °C for 5 minutes, 
and then
 chilled on ice. For the ﬁ  rst-strand cDNA 
synthesis, a heat-denatured
 RNA solution, along 
with 2 × ﬁ  rst-strand reaction mix and the Super-
Script III/RNase OUT enzyme mix, was added to 
make up 20 µL of the reaction mixture, followed
 
by incubation at 50 °C for 50 minutes, and then 
heating at 85 °C
 for 5 minutes and cooling on ice. 
The following primers were designed to amplify 
300-bp long FANCC (NM_000136) cDNA: sense, 
5’-gggcctctctcctgttctga-3’ and antisense, 5’-gaggt-
cagggcttccaggct-3’.
 PCR was then performed as 
follows: denaturation for 2 minutes at 94 °C, 
followed by 25–30 cycles at 94 °C for 15 seconds, 
55 °C for 30 seconds, and 68 °C
 for 30 seconds. 
As a control, a GAPDH primer set was used (R&D 
Systems, Minneapolis, MN, U.S.A). 
Results
Expression proﬁ  les of human 
FA mRNAs 
To investigate the common expression patterns 
of the FA mRNA, we initially compared the 
abundance of ESTs among major human tissues 
and organs including the brain, heart, lung, liver, 
stomach, small intestine, colon, kidney, 
pancreas, testis, and ovary. In silico analysis 
revealed that the expression patterns of the FA Gene Regulation and Systems Biology 2007: 1 4
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mRNA differed considerably in human tissues 
and organs (Fig. 1). One characteristic feature 
of the expression patterns of FA genes was that 
FA  genes were less expressed in the heart but 
were relatively well expressed in the stomach, 
colon, testis, and ovary. We speculated that the 
expression of FA genes tends to be enriched in 
proliferative tissues. 
Next, we asked which transcription factor regu-
lates the FA/BRCA pathway. The E2F family of 
transcription factors plays pivotal roles in the cell 
cycle progression and DNA damage repair path-
ways (Bracken et al. 2004). Therefore, we searched 
for FA mRNAs in public databases where the E2F 
family of transcription factors was either overex-
pressed or knocked down. A GEO database search 
revealed the deposition of microarray data for 
FANCA, FANCC, FANCD1, FANCG, and FANCL 
(see Materials & Methods). FANCA and FANCL 
mRNAs were clearly upregulated in E2F1 overex-
pressed SKMEL-2 melanoma cells, whereas 
FANCD1 and FANCG mRNAs were unchanged 
after E2F1 overexpression. On the other hand, the 
upregulation of FANCC mRNA by E2F1 was 
shown by one probe used in a microarray experi-
ment but not by other probes. To substantiate the 
E2F1-regulated FANCC mRNA expression, human 
normal lung ﬁ  broblast WI-38 cells were infected 
with an adenovirus expressing E2F1. A Western 
blot analysis revealed that a faint band of endog-
enous E2F1 protein was detected in the control 
adenovirus-infected cell lysates, whereas signiﬁ  -
cant amounts of exogenous E2F1 protein were 
detected in the E2F1 overexpressed cell lysates 
(Fig. 2, left panel). Twenty-four hours after the 
virus infection, the FANCC mRNA level was found 
to be upregulated, while the GAPDH mRNA level 
remained unchanged (Fig. 2, right panel). This 
Figure 1. Expression proﬁ  les of FA. A search was conducted based on the EST counts in human tissues and organs in the UniGene data-
base (NCBI, NIH). The data sets used for the FA genes are listed in Table 1. The number of transcripts per million was calculated from the 
gene EST/total EST in the pool.
0
20
40
60
80
100
120
140
Brain 
Heart 
Lung 
Liver 
Stomach 
Small intestine 
Colon 
Kidney 
Pancreas 
Testis 
Ovary 
FANCA 
FANCB 
FANCC 
FANCD1 
FANCD2 
FANCE 
FANCF 
FANCG 
FANCJ 
FANCL 
FANCM 
T
r
a
n
s
c
r
i
p
t
s
 
p
e
r
 
m
i
l
l
i
o
nGene Regulation and Systems Biology 2007: 1 5
E2Fs Regulate Fanconi Anemia Pathway
result suggests that FANCC could be a downstream 
target gene of E2F1. 
Transcriptional regulation of human 
FA genes
To gain more insight into the E2F-regulation of FA 
genes, we searched the proximal region of the 
transcription start site for potential cis-elements 
using Transfac software (ver. 4.0, cut off 85). We 
focused on the identification of E2F-binding 
consensus binding sequences within 1.5-kbp 
upstream and 0.5-kbp downstream of the transcrip-
tion start site. At least one or up to three E2F-
binding consensus sequences were identiﬁ  ed for 
all FA genes except the FANCM gene (Fig. 3A). 
To demonstrate the importance of the putative 
E2F-binding element for basal promoter activity, 
we generated promoter-luciferase constructs. 
These promoter constructs were used to study 
transient gene expression by transfecting them 
into HeLa cells and evaluating the ﬁ  reﬂ  y lucif-
erase activities by measuring the chemilumines-
cence with a luminometer. The transfection efﬁ  -
ciency was normalized by the dual luciferase 
assay, in which the corresponding Renilla lucif-
erase activity upon co-transfection of the pRL-TK 
plasmid was also measured. As shown in Figure 
3B, the FA promoter constructs used in this study 
showed various extents of increased activity, as 
determined by measuring the relative luciferase 
activities, when the activity of the control lucif-
erase vector, pGL3-Basic, was deﬁ  ned as 1. The 
exogenous coexpression of E2F1 caused up to 
approximately 4.5-, 2.5-, and 7.0-fold increases 
in the FANCA, FANCC, and FANCJ promoter 
activities, respectively, compared to that of the 
pcDNA3 control vector (Fig. 3C). The promoter 
regions cloned for FANCL were slightly upregu-
lated by the co-expression of E2F1. These results 
suggest that the E2F-binding motif(s) of the 
promoter constructs plays critical roles in the 
E2F1-mediated human FANCA, FANCC, and 
FANCJ promoter activities. 
Next, we sought evidence to show that members 
of the E2F family transcriptionally regulated the 
FANCA, FANCC, and FANCJ genes. As shown in 
Figure 3D, the exogenous co-expression of 
E2F1 ~ E2F4 caused an increase in the human 
FANCA, FANCC, and FANCJ promoter constructs, 
whereas the co-expression of E2F5 or E2F6 was 
associated with no increase in promoter activity, 
compared to that in the pcDNA3 control vector. In 
contrast, the co-expression of E2F1 ~ E2F6 was 
associated with no increase in pGL3-Basic 
promoter activity (data not shown). 
Discussion 
Each FA has its own characteristic features, but 
their functions commonly belong to the same 
categories, such as DNA damage repair or S phase 
progression. In the present work, we investigated 
the common transcriptional regulatory factors that 
regulate FA genes. First of all, we examined the 
Figure 2. E2F1 activates FANCC expression in WI-38 cells. (A) Cultures were infected with adenovirus encoding E2F1 or mock (control), 
and the E2F1 protein level was determined using a Western blot analysis with an anti-E2F1 antibody. Molecular weights (kDa) are shown 
on the left. The position of the E2F1 protein is indicated by the arrow on the right. RNA was extracted from WI-38 cells 24 hours after infec-
tion and analyzed using RT-PCR for FANCC and GAPDH.
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Figure 3. Transcriptional regulation of the human FA genes. (A) Schematic representation of the vicinity of the transcription start sites of 
the FA genes. The putative transcription factor E2F-binding sites (closed box) were searched within 1.5-kbp upstream and 0.5-kbp down-
stream of the transcription start sites, and are indicated with their scores (maximum score, 100) as calculated by the Transfac program. 
The transcription start sites (dotted lines) are indicated. The positions of the promoter constructs are numbered relative to the transcrip-
tion initiation site at +1, as described in the NCBI UniGene database (NCBI, NIH). (B) FA promoter activities in asynchronously growing 
human cells. HeLa cells were transfected with 200 ng of reporter constructs and 400 ng of the expression vector for E2F1, together with 
0.6 ng of pRL-TK. The pcDNA3 vector was used as a negative control. At 24 hours after the transfection, the cells were harvested and 
the extracts were prepared to measure the ﬁ  reﬂ  y and Renilla luciferase activities. Values are represented as the relative luciferase 
activities, with that of pGL3-Basic being deﬁ  ned as 1. (C) The E2F-binding motif(s) of the FANCA, FANCC, FANCJ, and FANCL promot-
ers are sufﬁ  cient to confer responses to ectopic E2F1 expression. The experiment was performed as described in (B). Values are 
represented as relative luciferase activities, with that of the control vector pcDNA3 being taken as 1. (D) Activation of the FA promoters 
by members of the E2F family. The experiment was performed as described in (B). Values are represented as the relative luciferase activities, 
with that of the control vector pcDNA3 being deﬁ  ned as 1. 
abundance of ESTs of FA in various human tissues 
and organs. This approach provided little informa-
tion regarding the framework of the regulatory 
network of FA genes. Because we had been inves-
tigating the transcriptional network of E2F 
transcription factors, we noted that recent compre-
hensive gene expression profiling of the E2F 
transcriptome had pinpointed some FA genes under 
the E2F pathway (Fig. 4). Notably, a microarray 
approach revealed that FANCA could be regulated 
by E2Fs like E2F1, E2F2, and E2F3 (Vernell et al. 
2003). By applying chromatin immunoprecipita-
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tion to isolate E2F4-bound sequences, the promoter 
regions of FANCD2, FANCG, and FANCL were 
shown to be potentially regulated by E2F4 (Wein-
mann et al. 2002; Cam et al. 2004). In addition, 
databases deposited in NCBI revealed that FANCA, 
FANCL, and probably FANCC genes were upregu-
lated in E2F1-overexpressed SKMEL-2 melanoma 
cells. We demonstrated
 that the overexpression of 
E2F1 in human diploid primary ﬁ  broblast WI-38 
cells upregulated FANCC mRNA expression. This 
evidence prompted us to examine the extent to 
which E2Fs contribute to the transcriptional regu-
lation of FA genes. 
We prospectively analyzed the promoter regions 
of the eleven known FA genes using an in silico 
determination of the putative E2F1 consensus site 
and promoter analysis based on a luciferase reporter 
assay. From these studies, the promoter regions 
cloned for FANCA, FANCC, and FANCJ were found 
to be upregulated by the co-expression of E2F1; 
this evidence enabled us to propose a novel gene 
regulatory network that couples the E2F1 and FA/
BRCA pathways (Fig. 4). FANCD2, FANCG, and 
FANCL may have E2F-responsive sites other than 
the region used in this study. Promoter analyses for 
mutations and the methylation status of FA genes 
have been well characterized; these statuses are 
known to affect the FA/BRCA pathway (Taniguchi 
et al. 2003). Among FA genes, the promoter of 
FANCC has been cloned and shown to be regulated 
by p53 (Savoia et al. 1995; Liebetrau et al. 1997). 
Once functional links between the E2F1 and FA/
BRCA pathways have been established, the 
complete system biology of the FA/BRCA pathway 
could be analyzed by examining their promoter 
regulation by cell cycle-associated key transcrip-
tional regulators, including p53. 
BRCA1, a familial breast and ovarian cancer 
susceptibility gene, encodes nuclear phosphopro-
teins that function as tumor suppressors in human 
Figure 4. Model depicting the E2Fs-FA/BRCA axis in the control of cell fate. The model shown depicts the E2F-regulated expression of the 
FA/BRCA pathway as key determinants for cells entering into the DNA damage/repair pathway or the S phase of the cell cycle. Otherwise, 
cells go into apoptosis, which is exclusively regulated by E2F1 among the E2Fs. The promoter regions cloned for FANCA, FANCC, and 
FANCJ were identiﬁ  ed as target sequences of E2Fs in the present study (surrounded by box). The regulation of FANCD2, FANCG, and 
FANCL as well as BRCA1 by E2Fs has also been previously reported or deposited in the public database (underlined). As posttranslational 
events, FANCA, FANCC, FANCE, FANCF, FANCG, and FANCL proteins trigger monoubiquitination of the FANCD2 protein during the S 
phase of the cell cycle and after DNA damage. Monoubiquitinated
 FANCD2 colocalizes in nuclear foci with BRCA1, FANCD1, and NBS1.
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breast cancer cells. BRCA1 serves as an important 
negative regulator of the cell cycle through its 
interaction with E2F transcriptional factors and 
phosphorylation by cyclins/cdk (cyclin-dependent 
kinase) complexes (Wang et al. 1997). Moreover, 
the regulation of BRCA1 expression by the pRb 
(retinoblastoma protein)/E2Fs pathway has been 
extensively characterized (Wang et al. 2000; 
Oberley et al. 2003; Bindra and Glazer, 2006). The 
FA/BRCA pathway may be a pivotal effector regu-
lated by activator-E2F signaling under the speciﬁ  c 
circumstance of DNA damage. Considering the 
predisposition to neoplasia, pRb mutations were 
expected to result in activator E2F overexpression; 
the subsequent expression of FA proteins might 
then compromise DNA damage, preventing the 
cells from progressing into a cancer phenotype.  
In conclusion, we found that the FA/BRCA
 
pathway is regulated by activator E2Fs responsible 
for the execution of the DNA damage/repair 
pathway. Most importantly, this pathway enables 
mechanistic links between E2F1 and FA genes, 
illuminating the molecular basis of DNA damage/
repair and S phase progression. We propose that 
the present analysis might be used as
 a research 
working model to approach system biology, in 
combination with in silico and functional analyses, 
for a comprehensive characterization of cellular 
events in any given organism. 
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